Genix Pharmaceuticals Corporation
GENPF · OTC
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.46 | -0.00 | 0.12 | -0.06 |
| FCF Yield | -5.67% | -8.95% | -5.06% | -4.87% |
| EV / EBITDA | 83.67 | -0.78 | -10.54 | -7.79 |
| Quality | ||||
| ROIC | 65.57% | 140.75% | -30.49% | -40.69% |
| Gross Margin | 32.02% | 26.43% | 0.00% | 0.00% |
| Cash Conversion Ratio | 2.56 | 0.05 | 0.20 | 0.26 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 15.11% | 1.01% | 47.95% | -110.96% |
| Safety | ||||
| Net Debt / EBITDA | 16.39 | -0.13 | -0.40 | 0.08 |
| Interest Coverage | -1.99 | -16.85 | -84.98 | -471.21 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.06 | 3.29 | 110.98 |
| Cash Conversion Cycle | -19,300.58 | -3,572.28 | -26.93 | -4.65 |